Eli Lilly and Company implemented a significant price reduction for its diabetes and weight-loss drugs, Mounjaro and Zepbound, in the Canadian market. The change became effective today, December 29, 2025. Lilly communicated the price cut, which amounts to 20% or more, to pharmacies in mid-December.
The new pricing structure lowers the list price for a four-week supply of the drugs. The 2.5 mg and 5 mg doses now cost CAD 300. Higher doses, specifically the 7.5 mg and 10 mg strengths, are priced at CAD 420.
Lilly enacted the reduction in response to competitive pressures within the market. The move also addresses upcoming changes to Canada's Patented Medicine Prices Review Board regulations.
No significant market reaction was reported today specifically tied to the implementation, as the announcement occurred earlier in the month. Earlier reports focused on the strategic implications for the Canadian pharmaceutical market, not immediate, major stock fluctuations.